What it's for (Indications)
- Tranexamic acid is a synthetic derivative of the amino acid lysine, primarily indicated for the treatment and prevention of excessive bleeding in various clinical scenarios by inhibiting fibrinolysis.
- Its therapeutic utility spans across multiple medical and surgical specialties.
- Key indications include the management of heavy menstrual bleeding (menorrhagia), where it significantly reduces blood loss, improving quality of life for affected individuals.
- It is also approved for short-term use in patients with hemophilia to prevent or reduce hemorrhage during and after tooth extractions, as well as other minor surgical procedures.
- Furthermore, tranexamic acid is widely utilized off-label for the prevention and treatment of bleeding in various surgical settings, such as cardiac surgery, orthopedic surgery (e.
- g.
- , total knee or hip arthroplasty), prostatectomy, and liver transplantation, where it effectively minimizes perioperative blood loss and transfusion requirements.
- Other important indications include the treatment of epistaxis (nosebleeds), gastrointestinal bleeding, and the prevention of attacks in patients with hereditary angioedema.
- Its role in postpartum hemorrhage management has also gained significant recognition, contributing to global maternal health initiatives by reducing life-threatening blood loss after childbirth.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Tranexamic acid is available in both oral tablet and intravenous (IV) formulations, with dosage regimens highly dependent on the specific indication, patient's renal function, body weight, and route of administration. For heavy menstrual bleeding (menorrhagia), the typical oral dosage is 1300 mg (two 650 mg tablets) administered three times daily for a maximum of 5 days during menstruation. In patients with hemophilia undergoing tooth extractions, an intravenous dose of 10 mg/kg is often given immediately before surgery, followed by oral administration of 25 mg/kg three to four times daily for 2 to 8 days. For general surgical bleeding prophylaxis or treatment, common intravenous regimens involve an initial loading dose, such as 10 mg/kg, followed by a continuous infusion of 1 mg/kg/hour. In cases of postpartum hemorrhage, a common recommendation is 1 gram intravenously administered within 3 hours of birth, with a potential repeat dose if bleeding persists or recurs within 30 minutes. Critical consideration must be given to dose adjustment in patients with impaired renal function to prevent drug accumulation and potential toxicity, often requiring a reduction in dose or frequency based on creatinine clearance. |
Safety & Warnings
Common Side Effects
- While generally well-tolerated, tranexamic acid can cause a range of side effects, varying in severity.
- Common adverse reactions primarily involve the gastrointestinal system, including nausea, vomiting, diarrhea, and abdominal pain.
- Headaches, back pain, and muscle cramps are also frequently reported.
- A significant and potentially serious side effect is visual disturbance, such as impaired color vision, which necessitates immediate discontinuation of the drug and an ophthalmological evaluation.
- The most critical and severe adverse effects are related to its mechanism of action: thromboembolic events.
- These include deep vein thrombosis (DVT), pulmonary embolism (PE), arterial thrombosis, stroke, and myocardial infarction, especially in patients with pre-existing risk factors or a history of such events.
- Hypersensitivity reactions, ranging from mild skin rashes to severe anaphylaxis, although rare, can occur.
- Rapid intravenous injection may lead to hypotension.
- Convulsions or seizures have been reported, particularly with high doses, rapid IV administration, or in patients with a history of epilepsy or underlying central nervous system disorders, emphasizing the importance of careful dosing and administration.
Serious Warnings
- Black Box Warning: Tranexamic acid does not carry a formal FDA Black Box Warning. However, healthcare professionals and patients must be fully aware of the significant and potentially life-threatening risks associated with its use. Therefore, this section serves as a **Serious Warnings** advisory. The primary concern revolves around the increased risk of **thromboembolic events**. Tranexamic acid, by inhibiting fibrinolysis, can promote clot stability to an extent that it may increase the risk of thrombotic complications, including deep vein thrombosis (DVT), pulmonary embolism (PE), arterial thrombosis (e.g., myocardial infarction, stroke), and cerebral thrombosis. This risk is particularly elevated in patients with a pre-existing history of thromboembolic disease, those with known thrombophilic conditions, individuals using concomitant hormonal contraceptives, or patients undergoing surgical procedures with a high risk of thrombosis. Careful patient selection, thorough assessment of thrombotic risk factors, and vigilant monitoring for signs and symptoms of thromboembolic events are crucial during treatment. In cases where concomitant hormonal contraceptives are being used, the combined risk of thrombosis must be carefully weighed against the benefits of tranexamic acid. If thrombotic events occur, tranexamic acid should be immediately discontinued. Furthermore, there is a risk of **visual disturbances**, including impaired color vision or retinal occlusions, necessitating ophthalmological examination before and during long-term treatment, and immediate discontinuation if visual changes develop.
- Tranexamic acid carries several critical warnings that require careful consideration before and during treatment.
- A primary concern is the increased risk of thromboembolic events, including deep vein thrombosis, pulmonary embolism, and arterial thrombosis (e.
- g.
- , stroke, myocardial infarction).
- This risk is elevated in patients with a personal or family history of thrombotic disease, those taking concomitant hormonal contraceptives, or individuals with other prothrombotic conditions.
- Close monitoring for signs and symptoms of thrombosis is essential.
- Patients receiving long-term therapy, particularly for conditions like hereditary angioedema, should undergo regular ophthalmological examinations, including visual acuity, color vision, and fundoscopy, as visual field loss or color vision impairment has been reported.
- Should visual disturbances occur, the drug must be discontinued.
- Convulsions have been reported, especially with high intravenous doses or in patients with a history of seizures; therefore, the recommended dosage should not be exceeded, and IV administration should be slow.
- Tranexamic acid is contraindicated in patients with acquired defective color vision as this could mask a potential ocular toxicity.
- Dose adjustment is imperative in patients with renal impairment to prevent accumulation and systemic toxicity.
- Not recommended for subarachnoid hemorrhage due to the potential risk of cerebral edema and infarction.
- Use in disseminated intravascular coagulation (DIC) should be approached with extreme caution and only if fibrinolytic activation is predominant, and under concomitant heparin therapy.
How it Works (Mechanism of Action)
Tranexamic acid functions as a potent antifibrinolytic agent, a synthetic analog of the amino acid lysine. Its primary mechanism of action involves reversibly binding to specific lysine-binding sites on plasminogen and plasmin. By occupying these sites, tranexamic acid effectively inhibits the binding of plasminogen to fibrin, thereby preventing the activation of plasminogen to its active form, plasmin, at the surface of the clot. Furthermore, it directly, though to a lesser extent, inhibits the proteolytic activity of plasmin itself. Plasmin is the key enzyme responsible for fibrinolysis, the breakdown of fibrin clots, which is a crucial step in the dissolution of blood clots. By impeding plasmin-mediated degradation of fibrin, tranexamic acid stabilizes the existing blood clots, thereby promoting hemostasis and reducing excessive bleeding. This action helps to maintain clot integrity and prevents premature lysis of hemostatic plugs. Beyond its direct antifibrinolytic properties, tranexamic acid also possesses some anti-inflammatory effects, potentially by inhibiting plasmin-mediated activation of complement and kinin systems, which can contribute to its overall therapeutic benefits in certain bleeding disorders.